Clinical Overview
Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with water, with or without meals, at the same time every day. Maintain regular blood glucose checks.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Upper respiratory tract infection, nasopharyngitis, headache, diarrhea, abdominal pain. Rare/Severe: Acute pancreatitis (including fatal necrotizing pancreatitis), severe and disabling arthralgia, bullous pemphigoid, and severe hypersensitivity (anaphylaxis, Stevens-Johnson syndrome).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Discontinue immediately if persistent severe abdominal pain radiating to the back occurs. Dosage must be reduced in patients with renal impairment (50 mg once daily if eGFR 30-44 mL/min; 25 mg once daily if eGFR < 30 mL/min).
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Dapagliflozin Tablets 10 mg
Dapagliflozin (5 mg, 10 mg) is a pioneer selective sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. It acts in the S1 segment of the renal proximal tubule, blocking glucose and sodium reabsorption and promoting the urinary excretion of 70 to 80 grams of glucose per day. In addition to glycemic reduction, it induces osmotic diuresis, decreases intraglomerular pressure, reduces cardiac preload and afterload, and confers landmark cardio-renal protection. Indicated for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction (HFrEF/HFpEF), and chronic kidney disease (CKD) to slow renal decline.
Sitagliptin Phosphate 50mg & Metformin Hydrochloride 500mg Tablets
Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Sitagliptin Phosphate Tablets 100mg
Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.
Sitagliptin Phosphate Tablets 50mg
Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.